Full-Time
Senior Project Manager
Operating Room Renovation
Updated on 7/21/2026
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
Compensation Overview
$102.6k - $188.1k/yr
Company Historically Provides H1B Sponsorship
Austin, TX, USA + 2 more
More locations: Dallas, TX, USA | United States
Hybrid
Hybrid role with up to 60% travel; some on-site work required.
 Business & Strategy (1) |
|---|
Get referred to Stryker
Find people who can refer or advise you
- Experience managing construction projects, renovations, remodels, or capital projects.
- Proven success overseeing contractors, construction scopes, demolition/tear-down activities, and project execution.
- Strong ability to manage multiple complex projects simultaneously.
- Excellent communication, stakeholder management, and problem-solving skills.
- Education: B.B.A or B.S in business or related curriculum.
- Preferred construction project management experience.
- Excellent interpersonal communication skills.
- Excellent analytical skills.
- Excellent organizational skills.
- 6+ of related experience.
- Must be able to resolve complex issues of a broad scope using independent judgment.
- Must be able to routinely make decisions which affect immediate operations and may have a division-wide effect.
- Must be able to communicate with others in large groups and virtually.
- Must be able to drive an automobile.
- Medium work: Exerting up to 50 pounds of force occasionally and/or up to 20 pounds of force constantly to move objects.
- Travel Percentage: 60%
- Lead OR renovation and new construction projects from quote through customer sign-off.
- Develop and manage project scopes, budgets, schedules, and contractor relationships.
- Oversee demolition, site preparation, construction activities, and installation readiness.
- Coordinate contractors, architects, facility leaders, and healthcare stakeholders throughout the project lifecycle.
- Drive project planning, risk mitigation, vendor management, and customer satisfaction.
- Ensure projects are delivered on time, within budget, and to the highest quality standards.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Vascular division jumped 27.5% following Inari acquisition, boosting organic growth outlook.
- Trident II Acetabular System launched in India, targeting rising hip replacement demand from aging populations.
- Free cash flow rose 227% to $415 million, strengthening capital efficiency and investor returns.
What critics are saying
- March 11, 2026 cyberattack by Handala disrupted global manufacturing, causing high-impact Q1 earnings miss.
- BofA cut price target to $380 on medtech slowdown, reducing 2027 earnings estimates due to soft utilization.
- Intuitive Surgical's 39x earnings vs Stryker's 22x risks valuation erosion in joint-replacement markets.
What makes Stryker unique
- Pangea Plating System launched in Europe on May 26, 2026, addressing diverse fractures without plate bending.
- Mako-driven orthopaedics franchise grows with integrated robotics for total joint and trauma procedures.
- TPX HD power tool delivers 296% more torque for demanding orthopaedic revision surgeries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…
Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.
Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.
Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.
Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.